Effects of Empagliflozin on Gut Microbiota in Heart Failure with a Preserved Ejection Fraction: The Design of a Pragmatic Randomized, Open-Label Controlled Trial (EMPAGUM)

Although empagliflozin has been recommended for individuals with heart failure, its effects on heart failure with preserved ejection fraction (HFpEF) remain uncertain from a physiopathological standpoint. The metabolites produced by gut microbiota have been shown to have a crucial role in the develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Xue-Qing, Wang, Chuan-He, Cheng, Peng, Fu, Ling-Yu, Wu, Qi-Jun, Cheng, Gong, Guan, Lin, Sun, Zhi-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202117/
https://www.ncbi.nlm.nih.gov/pubmed/37223722
http://dx.doi.org/10.2147/DDDT.S404479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202117/
https://www.ncbi.nlm.nih.gov/pubmed/37223722
http://dx.doi.org/10.2147/DDDT.S404479

Ejemplares similares